Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th

Rhea-AI Summary

Emmaus Life Sciences (OTCQX: EMMA) announced that its CEO, Yutaka Niihara, will present live on VirtualInvestorConferences.com on December 16 at 12:30 PM ET. Investors can engage with the company during this interactive online event, which will also be archived for later viewing. Attendees are encouraged to pre-register and check their systems for a smooth experience. Emmaus Life Sciences specializes in treating sickle cell disease and markets FDA-approved Endari, aimed at reducing acute complications of the condition.

TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, will present live at VirtualInvestorConferences.com, at 12:30 pm ET on December 16^th.     

DATE:  Thursday, December 16^th       
TIME: 12:30 pm EST
LINK: https://bit.ly/3cIf2X6

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com.

About Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is part of the OTC Market Group's suite of investor relations services specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/emmaus-life-sciences-to-webcast-live-at-life-sciences-investor-forum-on-december-16th-301441217.html

SOURCE VirtualInvestorConferences.com

FAQ

When will Emmaus Life Sciences present at Virtual Investor Conferences?

Emmaus Life Sciences will present live on December 16 at 12:30 PM ET.

Who is presenting for Emmaus Life Sciences at the investor conference?

Yutaka Niihara, M.D., M.P.H., Chairman and CEO, will present.

How can I attend the Emmaus Life Sciences presentation?

You can attend the presentation by registering on VirtualInvestorConferences.com.

Will the Emmaus Life Sciences presentation be available later?

Yes, the presentation will be archived for later viewing.

What product does Emmaus Life Sciences market for sickle cell disease?

Emmaus Life Sciences markets Endari, an FDA-approved treatment for sickle cell disease.

What is the focus of Emmaus Life Sciences?

Emmaus Life Sciences focuses on treating sickle cell disease and developing therapies for rare diseases.